论文部分内容阅读
目的:对多发性骨髓瘤(MM)患者应用硼替佐米治疗的临床效果进行探讨与研究。方法:初治MM患者48例,分成研究组和对照组,每组24例。研究组给予BDT方案治疗(硼替佐米+地塞米松+沙利度胺),对照组给予CDT方案治疗(环磷酰胺+地塞米松+沙利度胺)。对2组的诱导化疗效果进行观察与对比。结果:研究组中有10例CR(41.7%),6例VGPR(25%),4例PR(16.6%),3例SD(12.5%),1例PD,OR率为83.3%。对照组中有2例CR(8.3%),3例VGPR(12.5%),10例PR(41.7%),7例SD(29.1%),2例PD(8.3%),OR率为62.5%。2组比较差异有统计学意义(P<0.05)。研究组患者的不良反应发生率为29.2%,对照组患者为16.7%,差异无统计学意义(P>0.05),其中周围神经病变、血小板减少、感染等是主要不良反应。结论:硼替佐米方案治疗MM的效果显著,能够改善患者的生存质量和预后,安全可靠,尽管会出现一些不良反应,但作为靶向性治疗新药,由硼替佐米组成的治疗方案是值得在临床推广。
Objective: To investigate the clinical effect of bortezomib in patients with multiple myeloma (MM). Methods: 48 newly diagnosed MM patients were divided into study group and control group with 24 cases in each group. The study group was given BDT regimen (bortezomib + dexamethasone + thalidomide) and the control group was given CDT regimen (cyclophosphamide + dexamethasone + thalidomide). The two groups of induction chemotherapy were observed and compared. Results: CR (41.7%), VGPR (6%), PR in 4 cases (16.6%), SD in 3 cases (12.5%) and PD in 1 case were included in the study group. The OR rate was 83.3%. There were 2 CR (8.3%), 3 VGPR (12.5%), 10 PR (41.7%), 7 SD (29.1%) and 2 PD (8.3%) in the control group, with an OR of 62.5%. The difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions was 29.2% in the study group and 16.7% in the control group, with no significant difference (P> 0.05). The peripheral neuropathy, thrombocytopenia and infection were the main adverse reactions. CONCLUSIONS: The bortezomib regimen was effective in treating MM, which improved the quality of life and prognosis of patients and was safe and reliable. Although some adverse reactions may occur, as a new targeted drug, the regimen consisting of bortezomib is worth Clinical promotion.